Grothey B, Lyu S, Quaas A, Simon A, Jung J, Schroder W
Cell Mol Life Sci. 2025; 82(1):112.
PMID: 40074836
PMC: 11904063.
DOI: 10.1007/s00018-025-05635-7.
Crepaldi T, Gallo S, Comoglio P
Pharmaceuticals (Basel). 2024; 17(4).
PMID: 38675409
PMC: 11054789.
DOI: 10.3390/ph17040448.
Kim J, Lee T, Lee M, Cho I, Ryu J, Kim Y
Cancers (Basel). 2024; 16(5).
PMID: 38473413
PMC: 10930669.
DOI: 10.3390/cancers16051056.
Altintas D, Comoglio P
Cancers (Basel). 2023; 15(18).
PMID: 37760640
PMC: 10526818.
DOI: 10.3390/cancers15184672.
Zhao X, Xing P, Song X, Zhao M, Zhao L, Dang Y
Nat Commun. 2021; 12(1):6489.
PMID: 34764264
PMC: 8586158.
DOI: 10.1038/s41467-021-26745-3.
Targeting HGF/c-MET Axis in Pancreatic Cancer.
Pothula S, Xu Z, Goldstein D, Pirola R, Wilson J, Apte M
Int J Mol Sci. 2020; 21(23).
PMID: 33271944
PMC: 7730415.
DOI: 10.3390/ijms21239170.
MET targeting: time for a rematch.
Koch J, Aebersold D, Zimmer Y, Medova M
Oncogene. 2020; 39(14):2845-2862.
PMID: 32034310
DOI: 10.1038/s41388-020-1193-8.
Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors.
Hong D, LoRusso P, Hamid O, Janku F, Kittaneh M, Catenacci D
Clin Cancer Res. 2018; 25(8):2403-2413.
PMID: 30425090
PMC: 6892342.
DOI: 10.1158/1078-0432.CCR-18-1341.
Synthesis of novel 6,7-dimethoxy-4-anilinoquinolines as potent c-Met inhibitors.
Zhang Q, Ye Z, Shen C, Tie H, Wang L, Shi L
J Enzyme Inhib Med Chem. 2018; 34(1):124-133.
PMID: 30422010
PMC: 6237173.
DOI: 10.1080/14756366.2018.1533822.
Cell-Free DNA Profiling to Discover Mechanisms of Exceptional Response to Cabozantinib Plus Panitumumab in a Patient With Treatment Refractory Metastatic Colorectal Cancer.
Jia J, Morse M, Nagy R, Lanman R, Strickler J
Front Oncol. 2018; 8:305.
PMID: 30211110
PMC: 6121109.
DOI: 10.3389/fonc.2018.00305.
Expression of , and miR-134 as prognostic factors in esophageal cancer.
Klimczak-Bitner A, Kordek R, Bitner J, Musial J, Szemraj J
Oncol Lett. 2016; 12(5):4133-4138.
PMID: 27895782
PMC: 5104243.
DOI: 10.3892/ol.2016.5211.
Hepatocyte Growth Factor from a Clinical Perspective: A Pancreatic Cancer Challenge.
Rizwani W, Allen A, Trevino J
Cancers (Basel). 2015; 7(3):1785-805.
PMID: 26404380
PMC: 4586794.
DOI: 10.3390/cancers7030861.
Inhibition of ligand-independent constitutive activation of the Met oncogenic receptor by the engineered chemically-modified antibody DN30.
Vigna E, Chiriaco C, Cignetto S, Fontani L, Basilico C, Petronzelli F
Mol Oncol. 2015; 9(9):1760-72.
PMID: 26119717
PMC: 5528712.
DOI: 10.1016/j.molonc.2015.05.007.
Promise and challenges on the horizon of MET-targeted cancer therapeutics.
Zhang Y
World J Biol Chem. 2015; 6(2):16-27.
PMID: 26009700
PMC: 4436902.
DOI: 10.4331/wjbc.v6.i2.16.
Abl Kinases Regulate HGF/Met Signaling Required for Epithelial Cell Scattering, Tubulogenesis and Motility.
Li R, Knight J, Park M, Pendergast A
PLoS One. 2015; 10(5):e0124960.
PMID: 25946048
PMC: 4422589.
DOI: 10.1371/journal.pone.0124960.
Prognostic impact of the c-MET polymorphism on the clinical outcome in locoregional gastric cancer patients.
Sunakawa Y, Wakatsuki T, Yang D, Zhang W, Ning Y, Stintzing S
Pharmacogenet Genomics. 2014; 24(12):588-96.
PMID: 25203738
PMC: 4218879.
DOI: 10.1097/FPC.0000000000000091.
Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unit.
Gagliato D, Fontes Jardim D, Falchook G, Tang C, Zinner R, Wheler J
Clin Breast Cancer. 2014; 14(6):468-74.
PMID: 25065564
PMC: 4375949.
DOI: 10.1016/j.clbc.2014.06.001.
Tensin-4-dependent MET stabilization is essential for survival and proliferation in carcinoma cells.
Muharram G, Sahgal P, Korpela T, De Franceschi N, Kaukonen R, Clark K
Dev Cell. 2014; 29(4):421-36.
PMID: 24814316
PMC: 4118019.
DOI: 10.1016/j.devcel.2014.03.024.
Determination of crizotinib in human and mouse plasma by liquid chromatography electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS).
Roberts M, Turner D, Broniscer A, Stewart C
J Chromatogr B Analyt Technol Biomed Life Sci. 2014; 960:151-7.
PMID: 24811158
PMC: 4062842.
DOI: 10.1016/j.jchromb.2014.04.035.
MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit.
Fontes Jardim D, Gagliato D, Falchook G, Janku F, Zinner R, Wheler J
Oncotarget. 2014; 5(7):1837-45.
PMID: 24742823
PMC: 4039117.
DOI: 10.18632/oncotarget.1828.